We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




DNA Labels Simplify Development of Drug Delivery Nanoparticles

By LabMedica International staff writers
Posted on 21 Feb 2017
Print article
Image: A close-up image of a microfluidic chip used to fabricate nanoparticles that could be used to deliver therapeutic genes to specific organs of the body. Colored liquids have been added to highlight the channels (Photo courtesy of Rob Felt, Georgia Institute of Technology).
Image: A close-up image of a microfluidic chip used to fabricate nanoparticles that could be used to deliver therapeutic genes to specific organs of the body. Colored liquids have been added to highlight the channels (Photo courtesy of Rob Felt, Georgia Institute of Technology).
A team of biomedical engineers developed a method for labeling potential drug delivery nanoparticles with DNA "barcodes," which allowed the tracing of the nanoparticles within living test animals.

The effectiveness of nucleic acid drugs is limited by inefficient delivery to target tissues and cells and by unwanted accumulation in off-target organs. Although thousands of chemically distinct nanoparticles can be synthesized, nanoparticles designed to deliver nucleic acids in vivo were first tested in cell culture, yielding poor predictions for delivery in vivo. To facilitate testing of many nanoparticles in vivo, investigators at the Georgia Institute of Technology the University of Florida and the Massachusetts Institute of Technology designed and optimized a high-throughput DNA barcoding system to simultaneously measure nucleic acid delivery mediated by dozens of distinct nanoparticles in a single mouse.

The "barcodes" were short (approximately 58 nucleotides long) stretches of DNA, in the same size range as antisense oligonucleotides, microRNAs, and siRNAs (short inhibiting RNAs). A unique DNA barcode sequence was inserted into each type of nanoparticle carrier to be tested. The nanoparticles were injected into mice, whose organs were then examined for presence of the barcode using standard gene mapping techniques.

The investigators reported in the February 6, 2017, online edition of the journal Proceedings of the [U.S.] National Academy of Sciences that the method distinguished previously characterized lung- and liver- targeting nanoparticles and accurately reported relative quantities of nucleic acid delivered to tissues. Barcode sequences did not affect delivery, and no evidence of particle mixing was observed for tested particles. By measuring the bio-distribution of 30 nanoparticles to eight tissues simultaneously, they identified chemical properties promoting delivery to some tissues relative to others. Finally, particles that distributed to the liver also silenced gene expression in hepatocytes when formulated with siRNA.

"We want to understand at a very high level what factors affecting nanoparticle delivery are important," said first author Dr. James Dahlman, assistant professor of biomedical engineering at the Georgia Institute of Technology. "This new technique not only allows us to understand what factors are important, but also how disease factors affect the process. Nucleic acid therapies hold considerable promise for treating a range of serious diseases. We hope this technique will be used widely in the field, and that it will ultimately bring more clarity to how these drugs affect cells -- and how we can get them to the right locations in the body."

"In future work, we are hoping to make a thousand particles and instead of evaluating them three at a time, we would hope to test a few hundred simultaneously," said Dr. Dahlman. "Nanoparticles can be very complicated because for every biomaterial available, you could make several hundred nanoparticles of different sizes and with different components added."

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Specimen Collection & Transport
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.